DS9231-A-U201: ***EudraCT 2017-000552-25***

"**Evaluation of Safety and Thrombolytic Effect of Ascending Doses of DS9231 (TS23) in Subjects with Intermediate-Risk (Sub-Massive) Acute Pulmonary Embolism (PE)**"

Status: **Prematurely Ended**

Prior to the start of patient recruitment for the trial, Daiichi Sankyo cancelled the product development of DS-9231 due to business reasons. As a result, the scheduled clinical trial was prematurely terminated.

The investigational drug was not transported to any of the planned sites, and no patients were recruited or enrolled at any site worldwide. Therefore, no safety or efficacy data were collected or are available for reporting purposes on any national or regional clinical trial registry.